{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T03:54:23Z","timestamp":1775879663034,"version":"3.50.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-026-04272-3","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:56:03Z","timestamp":1775872563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of CHEK2 status on radiosurgical outcomes in breast cancer brain metastases"],"prefix":"10.1007","volume":"49","author":[{"given":"Paul M.","family":"Harary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke S.","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahed H.","family":"Kattaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sze Kiat","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred C.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmeen","family":"Zagzoog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armine","family":"Tayag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louisa","family":"Ustrzynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara C.","family":"Emrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris C.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"4272_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 71:209\u2013249","journal-title":"Cancer J Clin"},{"key":"4272_CR2","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","volume":"10","author":"EL Chang","year":"2009","unstructured":"Chang EL, Wefel JS, Hess KR et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10:1037\u20131044","journal-title":"Lancet Oncol"},{"key":"4272_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1748-717X-8-131","volume":"8","author":"JJ Jaboin","year":"2013","unstructured":"Jaboin JJ, Ferraro DJ, DeWees TA et al (2013) Survival following gamma knife radiosurgery for brain metastasis from breast cancer. Radiat Oncol 8:131","journal-title":"Radiat Oncol"},{"key":"4272_CR4","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.ijrobp.2008.12.031","volume":"75","author":"N Kased","year":"2009","unstructured":"Kased N, Binder DK, McDermott MW et al (2009) Gamma Knife radiosurgery for brain metastases from primary breast cancer. Int J Radiation Oncology* Biology* Phys 75:1132\u20131140","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"key":"4272_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s10585-015-9739-9","volume":"32","author":"D Smart","year":"2015","unstructured":"Smart D, Garcia-Glaessner A, Palmieri D et al (2015) Analysis of radiation therapy in a model of triple-negative breast cancer brain metastasis. Clin Exp Metastasis 32:717\u2013727","journal-title":"Clin Exp Metastasis"},{"key":"4272_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41420-024-02270-2","volume":"10","author":"PM Harary","year":"2024","unstructured":"Harary PM, Rajaram S, Chen MS et al (2024) Genomic predictors of radiation response: recent progress towards personalized radiotherapy for brain metastases. Cell Death Discovery 10:501","journal-title":"Cell Death Discovery"},{"key":"4272_CR7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/jmcb\/mju045","volume":"6","author":"L Zannini","year":"2014","unstructured":"Zannini L, Delia D, Buscemi G (2014) CHK2 kinase in the DNA damage response and beyond. J Mol Cell Biol 6:442\u2013457","journal-title":"J Mol Cell Biol"},{"key":"4272_CR8","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1086\/421251","volume":"74","author":"CHEK2 Breast Cancer Case-Control Consortium","year":"2004","unstructured":"CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2* 1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74:1175\u20131182","journal-title":"Am J Hum Genet"},{"key":"4272_CR9","doi-asserted-by":"publisher","first-page":"4308","DOI":"10.1200\/JCO.2012.42.7336","volume":"30","author":"M Weischer","year":"2012","unstructured":"Weischer M, Nordestgaard BG, Pharoah P et al (2012) CHEK2* 1100delC heterozygosity in women with breast cancer associated with early death, breast cancer\u2013specific death, and increased risk of a second breast cancer. J Clin Oncol 30:4308\u20134316","journal-title":"J Clin Oncol"},{"key":"4272_CR10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/sj.bjc.6604228","volume":"98","author":"L Mellemkjaer","year":"2008","unstructured":"Mellemkjaer L, Dahl C, Olsen J et al (2008) Risk for contralateral breast cancer among carriers of the CHEK2* 1100delC mutation in the WECARE Study. Br J Cancer 98:728\u2013733","journal-title":"Br J Cancer"},{"key":"4272_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2018.11.005","volume":"44","author":"D Akdeniz","year":"2019","unstructured":"Akdeniz D, Schmidt MK, Seynaeve CM et al (2019) Risk factors for metachronous contralateral breast cancer: a systematic review and meta-analysis. Breast 44:1\u201314","journal-title":"Breast"},{"key":"4272_CR12","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1158\/1055-9965.EPI-06-0687","volume":"15","author":"D Thompson","year":"2006","unstructured":"Thompson D, Seal S, Schutte M et al (2006) A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers. Cancer Epidemiol Biomarkers Prev 15:2542\u20132545","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"4272_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ijrobp.2015.05.037","volume":"93","author":"C Kan","year":"2015","unstructured":"Kan C, Zhang J (2015) BRCA1 mutation: a predictive marker for radiation therapy? Int J Radiation Oncology* Biology* Phys 93:281\u2013293","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"key":"4272_CR14","doi-asserted-by":"publisher","first-page":"S226","DOI":"10.1016\/j.ijrobp.2018.07.155","volume":"102","author":"K Pitter","year":"2018","unstructured":"Pitter K, Casey D, Setton J et al (2018) Pathogenic mutations in ATM as determinants of local control in non-small cell lung cancers treated with radiation therapy. Int J Radiat Oncol Biol Phys 102:S226","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4272_CR15","doi-asserted-by":"publisher","first-page":"101320","DOI":"10.1016\/j.adro.2023.101320","volume":"9","author":"W Floyd","year":"2024","unstructured":"Floyd W, Carpenter D, Vaios E et al (2024) Effects of Ataxia-Telangiectasia Mutated Variants on Radionecrosis and Local Control After Stereotactic Radiation Surgery for Non-Small Cell Lung Cancer Brain Metastases. Adv Radiation Oncol 9:101320","journal-title":"Adv Radiation Oncol"},{"key":"4272_CR16","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/annonc\/mdy216","volume":"29","author":"M Diossy","year":"2018","unstructured":"Diossy M, Reiniger L, Sztupinszki Z et al (2018) Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. Ann Oncol 29:1948\u20131954","journal-title":"Ann Oncol"},{"key":"4272_CR17","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1038\/s41467-022-30003-5","volume":"13","author":"A Rodriguez-Calero","year":"2022","unstructured":"Rodriguez-Calero A, Gallon J, Akhoundova D et al (2022) Alterations in homologous recombination repair genes in prostate cancer brain metastases. Nat Commun 13:2400. https:\/\/doi.org\/10.1038\/s41467-022-30003-5","journal-title":"Nat Commun"},{"key":"4272_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ijrobp.2016.06.009","volume":"96","author":"DM Trifiletti","year":"2016","unstructured":"Trifiletti DM, Lee C-C, Kano H et al (2016) Stereotactic radiosurgery for brainstem metastases: an international cooperative study to define response and toxicity. Int J Radiation Oncology* Biology* Phys 96:280\u2013288","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"key":"4272_CR19","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3171\/2024.7.JNS24920","volume":"142","author":"O Bin-Alamer","year":"2024","unstructured":"Bin-Alamer O, Abou-Al-Shaar H, Singh R et al (2024) Local control and patient survival after stereotactic radiosurgery for esophageal cancer brain metastases: an international multicenter analysis. J Neurosurg 142:1357\u20131365","journal-title":"J Neurosurg"},{"key":"4272_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11060-025-05039-4","volume":"174","author":"R Perron","year":"2025","unstructured":"Perron R, Iorio-Morin C, Chytka T et al (2025) International multicenter study of stereotactic radiosurgery for bladder cancer brain metastases. J Neurooncol 174:235\u2013241","journal-title":"J Neurooncol"},{"key":"4272_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1227\/neu.0000000000003609","volume":"98","author":"M Billau","year":"2026","unstructured":"Billau M, Hamel A, Tourigny J-N et al (2026) Multicenter retrospective study of stereotactic radiosurgery for gynecological cancer brain metastases. Neurosurgery 98:194\u2013203","journal-title":"Neurosurgery"},{"key":"4272_CR22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2006.07.038","volume":"66","author":"EJ Hall","year":"2006","unstructured":"Hall EJ, Giaccia AJ (2006) Radiobiology for the Radiologist. Int J Radiat Oncol Biol Phys 66:10\u20131016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4272_CR23","doi-asserted-by":"publisher","first-page":"362761","DOI":"10.1155\/2013\/362761","volume":"2013","author":"A Santacroce","year":"2013","unstructured":"Santacroce A, Kamp MA, Budach W, H\u00e4nggi D (2013) Radiobiology of radiosurgery for the central nervous system. Biomed Res Int 2013:362761","journal-title":"Biomed Res Int"},{"key":"4272_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, De Vries E et al (2016) RECIST 1.1\u2014Update and clarification: From the RECIST committee. Eur J Cancer 62:132\u2013137","journal-title":"Eur J Cancer"},{"key":"4272_CR25","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3171\/2022.10.JNS221900","volume":"138","author":"RO Kowalchuk","year":"2022","unstructured":"Kowalchuk RO, Niranjan A, Hess J et al (2022) Stereotactic radiosurgery and local control of brain metastases from triple-negative breast cancer. J Neurosurg 138:1608\u20131614","journal-title":"J Neurosurg"},{"key":"4272_CR26","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s10549-014-3242-x","volume":"149","author":"E Cho","year":"2015","unstructured":"Cho E, Rubinstein L, Stevenson P et al (2015) The use of stereotactic radiosurgery for brain metastases from breast cancer: who benefits most? Breast Cancer Res Treat 149:743\u2013749","journal-title":"Breast Cancer Res Treat"},{"key":"4272_CR27","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","volume":"363","author":"DW Andrews","year":"2004","unstructured":"Andrews DW, Scott CB, Sperduto PW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665\u20131672","journal-title":"Lancet"},{"key":"4272_CR28","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","volume":"18","author":"PD Brown","year":"2017","unstructured":"Brown PD, Ballman KV, Cerhan JH et al (2017) Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b7 3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 18:1049\u20131060","journal-title":"Lancet Oncol"},{"key":"4272_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","volume":"15","author":"M Yamamoto","year":"2014","unstructured":"Yamamoto M, Serizawa T, Shuto T et al (2014) Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15:387\u2013395","journal-title":"Lancet Oncol"},{"key":"4272_CR30","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ijrobp.2019.03.052","volume":"104","author":"RT Hughes","year":"2019","unstructured":"Hughes RT, Masters AH, McTyre ER et al (2019) Initial SRS for patients with 5 to 15 brain metastases: results of a multi-institutional experience. Int J Radiation Oncology* Biology* Phys 104:1091\u20131098","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"key":"4272_CR31","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.ijrobp.2020.07.2108","volume":"108","author":"J Li","year":"2020","unstructured":"Li J, Ludmir E, Wang Y et al (2020) Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4\u201315 brain metastases: a phase III randomized controlled trial. Int J Radiat Oncol Biol Phys 108:S21\u2013S22","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4272_CR32","doi-asserted-by":"crossref","unstructured":"Mansouri A, Ozair A, Bhanja D et al (2025) Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care. Nat Reviews Clin Oncol 22(5):327\u2013347","DOI":"10.1038\/s41571-025-01013-1"},{"key":"4272_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ctrv.2013.05.002","volume":"40","author":"B Lippitz","year":"2014","unstructured":"Lippitz B, Lindquist C, Paddick I et al (2014) Stereotactic radiosurgery in the treatment of brain metastases: the current evidence. Cancer Treat Rev 40:48\u201359","journal-title":"Cancer Treat Rev"},{"key":"4272_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11864-021-00854-z","volume":"22","author":"BA Vellayappan","year":"2021","unstructured":"Vellayappan BA, McGranahan T, Graber J et al (2021) Radiation necrosis from stereotactic radiosurgery\u2014how do we mitigate? Curr Treat Options Oncol 22:57","journal-title":"Curr Treat Options Oncol"},{"key":"4272_CR35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/01.nrl.0000080951.78533.c4","volume":"9","author":"P Giglio","year":"2003","unstructured":"Giglio P, Gilbert MR (2003) Cerebral radiation necrosis. Neurologist 9:180\u2013188","journal-title":"Neurologist"},{"key":"4272_CR36","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1200\/PO.19.00178","volume":"4","author":"SL Greville-Heygate","year":"2020","unstructured":"Greville-Heygate SL, Maishman T, Tapper WJ et al (2020) Pathogenic variants in CHEK2 are associated with an adverse prognosis in symptomatic early-onset breast cancer. JCO Precision Oncol 4:472\u2013485","journal-title":"JCO Precision Oncol"},{"key":"4272_CR37","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ccr.2010.10.034","volume":"18","author":"M Squatrito","year":"2010","unstructured":"Squatrito M, Brennan CW, Helmy K et al (2010) Loss of ATM\/Chk2\/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell 18:619\u2013629","journal-title":"Cancer Cell"},{"key":"4272_CR38","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/s41467-023-36878-2","volume":"14","author":"C Dmello","year":"2023","unstructured":"Dmello C, Zhao J, Chen L et al (2023) Checkpoint kinase 1\/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. Nat Commun 14:1566","journal-title":"Nat Commun"},{"key":"4272_CR39","doi-asserted-by":"publisher","first-page":"445","DOI":"10.18632\/oncotarget.28740","volume":"16","author":"H Qian","year":"2025","unstructured":"Qian H, Ali H, Karri V et al (2025) Beyond DNA damage response: Immunomodulatory attributes of CHEK2 in solid tumors. Oncotarget 16:445","journal-title":"Oncotarget"},{"key":"4272_CR40","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1038\/s41467-024-47998-8","volume":"15","author":"CI Ene","year":"2024","unstructured":"Ene CI, Abi Faraj C, Beckham TH et al (2024) Response of treatment-naive brain metastases to stereotactic radiosurgery. Nat Commun 15:3728","journal-title":"Nat Commun"},{"key":"4272_CR41","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","volume":"11","author":"L Nguyen","year":"2020","unstructured":"Nguyen L, Martens WM, Van Hoeck J, Cuppen A E (2020) Pan-cancer landscape of homologous recombination deficiency. Nat Commun 11:5584","journal-title":"Nat Commun"},{"key":"4272_CR42","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/ijms23010348","volume":"23","author":"H Yamamoto","year":"2021","unstructured":"Yamamoto H, Hirasawa A (2021) Homologous recombination deficiencies and hereditary tumors. Int J Mol Sci 23:348","journal-title":"Int J Mol Sci"},{"key":"4272_CR43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","volume":"27","author":"MD Stewart","year":"2022","unstructured":"Stewart MD, Merino Vega D, Arend RC et al (2022) Homologous recombination deficiency: concepts, definitions, and assays. Oncologist 27:167\u2013174","journal-title":"Oncologist"},{"key":"4272_CR44","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/cancers11050665","volume":"11","author":"M Tyran","year":"2019","unstructured":"Tyran M, Carbuccia N, Garnier S et al (2019) A comparison of DNA mutation and copy number profiles of primary breast cancers and paired brain metastases for identifying clinically relevant genetic alterations in brain metastases. Cancers 11:665","journal-title":"Cancers"},{"key":"4272_CR45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/2211-5463.12356","volume":"8","author":"J Li","year":"2018","unstructured":"Li J, Li M, Chen P, Ba Q (2018) High expression of PALB2 predicts poor prognosis in patients with advanced breast cancer. FEBS open bio 8:56\u201363","journal-title":"FEBS open bio"},{"key":"4272_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/jpm11040245","volume":"11","author":"L Cortesi","year":"2021","unstructured":"Cortesi L, Piombino C, Toss A (2021) Germline mutations in other homologous recombination repair-related genes than BRCA1\/2: Predictive or prognostic factors? J Personalized Med 11:245","journal-title":"J Personalized Med"},{"key":"4272_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13058-025-01988-w","volume":"27","author":"NM Viart","year":"2025","unstructured":"Viart NM, Renault A-L, Eon-Marchais S et al (2025) Breast tumors from ATM pathogenic variant carriers display a specific genome-wide DNA methylation profile. Breast Cancer Res 27:36","journal-title":"Breast Cancer Res"},{"key":"4272_CR48","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1086\/426403","volume":"75","author":"C Cybulski","year":"2004","unstructured":"Cybulski C, Gorski B, Huzarski T et al (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131\u20131135","journal-title":"Am J Hum Genet"},{"key":"4272_CR49","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41467-022-27987-5","volume":"13","author":"N Cosgrove","year":"2022","unstructured":"Cosgrove N, Vare\u0161lija D, Keelan S et al (2022) Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. Nat Commun 13:514","journal-title":"Nat Commun"},{"key":"4272_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10549-023-07115-7","volume":"203","author":"Y Ishizuka","year":"2024","unstructured":"Ishizuka Y, Horimoto Y, Eguchi H et al (2024) BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer. Breast Cancer Res Treat 203:49\u201355","journal-title":"Breast Cancer Res Treat"},{"key":"4272_CR51","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","volume":"5","author":"PK Brastianos","year":"2015","unstructured":"Brastianos PK, Carter SL, Santagata S et al (2015) Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 5:1164\u20131177","journal-title":"Cancer Discov"},{"key":"4272_CR52","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1038\/s41467-019-10987-3","volume":"10","author":"J Sun","year":"2019","unstructured":"Sun J, Wang C, Zhang Y et al (2019) Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases. Nat Commun 10:3190","journal-title":"Nat Commun"},{"key":"4272_CR53","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao S, Wu Q, McLendon RE et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756\u2013760","journal-title":"Nature"},{"key":"4272_CR54","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/cncr.21946","volume":"106","author":"GT Szeifert","year":"2006","unstructured":"Szeifert GT, Atteberry DS, Kondziolka D et al (2006) Cerebral metastases pathology after radiosurgery: a multicenter study. Cancer: Interdisciplinary Int J Am Cancer Soc 106:2672\u20132681","journal-title":"Cancer: Interdisciplinary Int J Am Cancer Soc"},{"key":"4272_CR55","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMct0806951","volume":"362","author":"JH Suh","year":"2010","unstructured":"Suh JH (2010) Stereotactic radiosurgery for the management of brain metastases. N Engl J Med 362:1119\u20131127","journal-title":"N Engl J Med"},{"key":"4272_CR56","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1172\/JCI97631","volume":"129","author":"S Bodo","year":"2019","unstructured":"Bodo S, Campagne C, Thin TH et al (2019) Single-dose radiotherapy disables tumor cell homologous recombination via ischemia\/reperfusion injury. J Clin Investig 129:786\u2013801","journal-title":"J Clin Investig"},{"key":"4272_CR57","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.7150\/jca.44408","volume":"11","author":"S Li","year":"2020","unstructured":"Li S, Shen L (2020) Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists. J Cancer 11:5056","journal-title":"J Cancer"},{"key":"4272_CR58","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/nop\/npaa067","volume":"8","author":"I Alnahhas","year":"2021","unstructured":"Alnahhas I, Rayi A, Palmer JD et al (2021) The role of VEGF receptor inhibitors in preventing cerebral radiation necrosis: a retrospective cohort study. Neuro-Oncology Pract 8:75\u201380","journal-title":"Neuro-Oncology Pract"},{"key":"4272_CR59","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.21037\/tlcr-20-1117","volume":"10","author":"ZZ Akanda","year":"2021","unstructured":"Akanda ZZ, Neeson PJ, John T et al (2021) A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer. Translational Lung Cancer Res 10:2766","journal-title":"Translational Lung Cancer Res"},{"key":"4272_CR60","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.ijrobp.2007.10.059","volume":"70","author":"C Park","year":"2008","unstructured":"Park C, Papiez L, Zhang S et al (2008) Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiation Oncology* Biology* Phys 70:847\u2013852","journal-title":"Int J Radiation Oncology* Biology* Phys"},{"key":"4272_CR61","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1088\/0031-9155\/49\/20\/012","volume":"49","author":"M Guerrero","year":"2004","unstructured":"Guerrero M, Li XA (2004) Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol 49:4825\u20134835","journal-title":"Phys Med Biol"},{"key":"4272_CR62","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1259\/0007-1285-62-740-679","volume":"62","author":"JF Fowler","year":"1989","unstructured":"Fowler JF (1989) The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62:679\u2013694","journal-title":"Br J Radiol"},{"key":"4272_CR63","unstructured":"Yadav S (2023) Carriers of CHEK2 mutations have a 2-Fold Increased risk for contralateral breast cancer, says expert. Cancer Network NA-NA"},{"key":"4272_CR64","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3390\/cells9122675","volume":"9","author":"L Stolarova","year":"2020","unstructured":"Stolarova L, Kleiblova P, Janatova M et al (2020) CHEK2 germline variants in cancer predisposition: stalemate rather than checkmate. Cells 9:2675","journal-title":"Cells"},{"key":"4272_CR65","doi-asserted-by":"publisher","first-page":"16142","DOI":"10.1002\/cam4.6272","volume":"12","author":"A Morra","year":"2023","unstructured":"Morra A, Schreurs MA, Andrulis IL et al (2023) Association of the CHEK2 c. 1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. Cancer Med 12:16142\u201316162","journal-title":"Cancer Med"},{"key":"4272_CR66","doi-asserted-by":"publisher","first-page":"eaaq1427","DOI":"10.1126\/scitranslmed.aaq1427","volume":"11","author":"FJ N\u00fa\u00f1ez","year":"2019","unstructured":"N\u00fa\u00f1ez FJ, Mendez FM, Kadiyala P et al (2019) IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Sci Transl Med 11:eaaq1427","journal-title":"Sci Transl Med"},{"key":"4272_CR67","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1074\/jbc.M009727200","volume":"276","author":"X Wu","year":"2001","unstructured":"Wu X, Webster SR, Chen J (2001) Characterization of Tumor-associated Chk2 Mutations *. J Biol Chem 276:2971\u20132974. https:\/\/doi.org\/10.1074\/jbc.M009727200","journal-title":"J Biol Chem"},{"key":"4272_CR68","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/annonc\/mdv022","volume":"26","author":"S Shiovitz","year":"2015","unstructured":"Shiovitz S, Korde LA (2015) Genetics of breast cancer: a topic in evolution. Ann Oncol 26:1291\u20131299. https:\/\/doi.org\/10.1093\/annonc\/mdv022","journal-title":"Ann Oncol"},{"key":"4272_CR69","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ijc.33199","volume":"148","author":"IM Akcay","year":"2021","unstructured":"Akcay IM, Celik E, Agaoglu NB et al (2021) Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls. Int J Cancer 148:285\u2013295","journal-title":"Int J Cancer"},{"key":"4272_CR70","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu C, Hart SN, Gnanaolivu R et al (2021) A population-based study of genes previously implicated in breast cancer. N Engl J Med 384:440\u2013451","journal-title":"N Engl J Med"},{"key":"4272_CR71","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13058-016-0758-5","volume":"18","author":"TA Muranen","year":"2016","unstructured":"Muranen TA, Blomqvist C, D\u00f6rk T et al (2016) Patient survival and tumor characteristics associated with CHEK2: p. I157T\u2013findings from the Breast Cancer Association Consortium. Breast Cancer Res 18:98","journal-title":"Breast Cancer Res"},{"key":"4272_CR72","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41591-022-01749-8","volume":"28","author":"C Monteiro","year":"2022","unstructured":"Monteiro C, Miarka L, Perea-Garc\u00eda M et al (2022) Stratification of radiosensitive brain metastases based on an actionable S100A9\/RAGE resistance mechanism. Nat Med 28:752\u2013765. https:\/\/doi.org\/10.1038\/s41591-022-01749-8","journal-title":"Nat Med"},{"key":"4272_CR73","doi-asserted-by":"crossref","unstructured":"Vogelbaum MA, Brown PD, Messersmith H et al (2022) Treatment for brain metastases. ASCO-SNO-ASTRO guideline","DOI":"10.1200\/JCO.21.02314"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04272-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-026-04272-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04272-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T03:41:11Z","timestamp":1775878871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-026-04272-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4272"],"URL":"https:\/\/doi.org\/10.1007\/s10143-026-04272-3","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study approved by the Stanford University Institutional Review Board panel on Medical Human Subjects (IRB-3910).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical approval"}},{"value":"Not applicable. This retrospective analysis using anonymized data did not require individual informed consent per the Stanford University Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable. This manuscript includes no identifiable patient data, images, or personal information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"346"}}